Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.
An officer of Veracyte, Inc. executed a programmed sale of 2,160 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan. The sale's weighted average price was approximately $35.00 per share (individual prices ranged $35.00–$35.05), and the reporting person retained beneficial ownership of 89,439 shares after the transactions. The filer notes the sales were made pursuant to a plan adopted on 9/04/2024, and that detailed per-price share counts are available on request.
Veracyte, Inc. filed a Form 144 reporting a proposed sale of 2,539 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/01/2025. The filing lists an aggregate market value of $87,163.87 based on 78,671,588 shares outstanding. The shares were acquired on 03/02/2024 as restricted stock units issued by the company and were paid on that same date. The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information regarding the issuer.
Veracyte (VCYT) reports a proposed sale of 2,160 common shares, representing restricted stock units acquired on 03/02/2025, with an aggregate market value of $74,152.80. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ. The issuer's outstanding shares are listed as 78,671,588, so the proposed sale equals approximately 0.0027% of outstanding shares. The filing also discloses prior 10b5-1 sales by the same account of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50. The securities were acquired as Restricted Stock Units from the issuer and no cash payment was required at acquisition.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.
The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.
Form 144 notice for Veracyte, Inc. (VCYT) reporting a proposed sale of 2,283 common shares, with an aggregate market value of $75,864.09, scheduled approximately for 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units on 06/02/2025 from the issuer and were fully issued on that date. The filer certifies there are no undisclosed material adverse facts and reports no other sales by the same person in the past three months. The filing provides basic transactional details but does not state the seller's identity or motivation for the sale.
Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), sold 7,667 shares of the company's common stock on 09/04/2025 under a pre-established Rule 10b5-1 trading plan adopted on 09/13/2024. The transaction was reported at a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66. After the reported sale, the filing shows Mr. Stapley beneficially owns 334,185 shares. The Form 4 was executed by an attorney-in-fact and includes customary disclosure that detailed per-price share breakdowns are available upon request.
Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported a Form 4 disclosing that on 09/02/2025 5,371 shares of Common Stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing shows 133,158 shares of Common Stock beneficially owned by the reporting person after the transaction. The transaction code is noted as F and the per-share price listed is $30.11, with the filer confirming the withholding was not a sale but a tax-related retention of shares.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported that 3,507 shares of common stock were withheld on 09/02/2025 to satisfy tax withholding tied to the vesting of restricted stock units; this withholding is not a sale and was executed at a per-share price of $30.11. After the withholding, McGuire beneficially owned 93,882 shares, which includes 386 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.